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Abstract: A metabonomics method using 
1H nuclear magnetic resonance spectroscopy 
(
1HNMR) was applied to obtain a systematic view of the development and progression of 
postmenopausal osteoporosis. Using partial least squares discriminant analysis (PLS-DA), 
26 and 34 characteristic resonances were found respectively in urine and plasma of 
ovariectomized rats (Variable importance, VIP value  ≥1.0),  and  the  significant altered 
metabolites identified in the plasma and urine were 10 and 9, respectively. Changes in these 
metabolites were related to the pathways of lipid, energy and amino acid metabolism, some 
of which involved the oxidative system. The described method was also used to analyze the 
therapeutic effects of Er-Xian Decoction (EXD), a traditional Chinese medicine widely  
used in the clinical treatment of osteoporosis in China. The results showed that EXD 
administration could provide satisfactory effects on osteoporosis through partially regulating 
the perturbed pathways of lipid, energy and amino acid metabolism and improving the 
anti-oxidative ability. 
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1 Introduction 
Postmenopausal osteoporosis, which is believed to be associated with ovarian hormone deficiency, is 
by far the most common cause of age-related bone loss [1]. With the reduction in estrogen levels, there is 
an increase in bone breakdown related to bone formation, microarchitectural deterioration and decreased 
bone mass [2]. Approximately 40 percent of women over 50 years suffer from osteoporotic fracture 
during their lifetime [3]. Estrogen replacement therapy (ERT) has been considered the most effective for 
the prevention and treatment of postmenopausal osteoporosis. However, an investigation [4,5] showed 
that estrogen could lead to higher occurrences of breast carcinoma, endometrial cancer and 
cardiovascular diseases. To develop a new substance with fewer undesirable side effects based on the 
pathological mechanism of postmenopausal osteoporosis, the biological processes of the condition need 
to be further investigated to find new biomarkers and illuminate the disease mechanism. 
Medicinal treatment of postmenopausal osteoporosis in China not only includes modern medicines 
but traditional Chinese herbal drugs. Er-Xian Decoction (EXD), a popular Chinese medicinal formula 
comprising Epimedium brevicornum Maxim. (Berberidaceae, whole herb), Curculigo orchioides Gaertn. 
(Amaryllidaceae,  rhizome),  Anemarrhena asphodeloides Bge.  (Liliaceae, rhizome)  Phellodendron 
chinense Schneid. (Rutaceae, bark), Morinda officinalis How. (Rubiaceae, root), Angelica sinensis 
(Oliv.) Diels (Umbelliferae, root), and in a compositional ratio of 9:9:6:6:9:9 have been used for the 
treatment of osteoporosis, menopausal syndrome and age-associated diseases in the past 50 years.  
A systemic review and Meta-analysis of 677 participants involved in 5 clinical investigations indicated 
that EXD was clinically effective in relieving menopausal syndrome via increasing the circulatory 
estradiol level [6,7]. EXD was also shown to have positive effects on bone in ovariectomized rats [8], 
and could increase proliferation and activity of alkaline phosphates (ALP) of primary osteoblastic cells, 
and decrease the formation, differentiation and tartrate-resistant acidic phosphates (TRAP) activity  
of osteoclast-like multinucleated cells (MNCs) induced from bone marrow cells of rat [9]. However,  
the action mechanism of EXD is not clearly defined due to complexity and interaction of the  
active components.  
Metabonomics, which is defined as the quantitative measurement of the dynamic multiparametric 
metabolic response of living systems to pathophysiological stimuli or genetic modification, has been 
used to characterize the biochemical pattern of endogenous metabolic composition in biological samples, 
and detect the physiopathological response to a drug and disease-induced disturbance in an endogenous 
metabolic network [10,11]. Estrogen deficiency in postmenopausal or ovariectomized women may 
cause  changes in many physiological processes, leading  to  occurrences of cardiovascular disease, 
obesity, osteoporosis and alteration of metabolites in blood and urine. In recent years, some studies have 
reported altered metabonomics in ovariectomized rats, a common model for assessing osteoporosis.  
The metabonomic analysis based on 
1HNMR in ovariectomized rats found that  ovareictomy for   
5 months lead to the elevated level of lactate, acetone and ethanol, and decreased level of glucose, 
choline/phosphatidylcholine, alanine, high density lipoprotein/low density lipoprotein (HDL/LDL), Int. J. Mol. Sci. 2011, 12                       
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very low density lipoprotein/low density lipoprotein, fatty acid in the plasma of rats  [12].  
A  GC-TOF/MS-based metabolomic investigation indicated that ovariectomy caused elevation in 
cholesterol, glycerol, glucose, arachidonic acid, glutamic acid, glycine, and cystine, and decline in 
alanine of serum in 12-month obese rats [13]. The metabonomic analysis using UPLC-q-TOF-MS 
demonstrated that the level of fatty acids such as arachidonic acid (AA), eicosapentaenoic acid (EPA) 
and cholecalciferol was increased, and the level of ergocalciferol was decreased in serum of 12-week 
rats with ovariectomy-induced estrogen deficiency [14]. However, there is no investigation reporting 
changes in bone metabolism tightly associated with estrogen withdrawal. The three detection methods 
applied in metabonomic analysis (
1HNMR, GC-MS and UPLC) have their advantages and limitations 
respectively. The 
1HNMR analytical method has the advantage of the simple fast sample preparation 
process, short measurement time, and advanced data analysis methods.  In  the  present study, a 
1HNMR-based metabonomic strategy was applied to find changed metabolites in urine and blood of 
osteoporotic ovariectomized rats with the purpose of gaining insights into the pathological process of 
postmenopausal osteoporosis. In addition, this is also the first study to investigate possible reverse 
effects of EXD and explore its action mechanism using a metabonomic approach. 
2. Experimental 
2.1. Materials  
The six plant materials of EXD were obtained from Hua Yu Pharmarceutical Company in Shanghai, 
China, and identified by Prof. H.C. Zheng of the Department of Pharmacognosy, School of Pharmacy of 
the Second Military Medical University in Shanghai, China. Their voucher specimens are available in 
the herbarium of this Department. A 1500 g mixture of six crud drugs in EXD with the weight ratio of 
9:9:6:6:9:9 was extracted by decocting the mixed herbs with 10× (v/w) distilled water at 100 °C for 2 h. 
After filtration, the residue was boiled for an additional 1 h. Filtrates were mixed together, lyophilized 
with a freeze drier (Labconco, Preezone), and kept at 4 °C. The yield of the dried extract from the 
starting crude materials was 10%. The EXD extracts resolved to 60 mg/mL in water were administered 
orally to rats at a volume of 1 mL/100 g body weight which equal to human daily dosage.  
The assay kits for alkaline phosphatase (ALP, A059-1), tartrate-resistant acid phosphatase (TRAP, 
A058), superoxide dismutase (SOD, A001), glutathione peroxidase (GPX, A005), and malondialdehyde 
(MDA, A003) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). RIA 
kits for measurement of estradiol levels were purchased from China Institute of Atomic Energy (Beijing, 
China, S20103078). 
2.2. Animals 
Twenty four female Sprague-Dawley  (SD)  rats  aged  12 weeks  were purchased from Slacom 
Experimental Animal Company (Shanghai, China,) and acclimated to conditions for 1 week before the 
experiment. The experimental animals were housed in an air-conditioned room with 12 h/12 h light-dark 
illumination cycles at constant temperature 25 ± 2 °C and humidity (50% ± 10%). Food and drinking 
water were supplied ad labitum. The rats were weighed weekly during the experimental period.  Int. J. Mol. Sci. 2011, 12                       
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2.3. Establishment of the Osteoporotic Model and Drug Administration 
The osteoporotic model was established by removing the bilateral ovaries of rat for 12 weeks. Of the 
24 female SD rats, 8 were sham-operated and treated with deionized water as the aging control group 
(sham). The remaining rats were bilaterally ovariectomized and equally randomized into two groups. 
They were treated with vehicle (deionized water) or EXD extract (600 mg·kg
−1·d
−1, ig) for 12 weeks, 
starting from day one of surgery. Success of ovariectomy was confirmed at necropsy by failure to detect 
the ovarian tissue and by observation of marked atrophy of the uterine horns. At the end of the treatment, 
the femurs were cleaned off from adhering soft tissues, and then enclosed with PBS-saturated gauze and 
stored in a freezer at −80 °C. Bone mineral density (BMD) was determined by dual-energy X-ray 
absorptiometry (LUNAR Co. Ltd., USA) using the small animal scan mode.  
2.4. Sample Collection 
The animals were weighed weekly during the experimental period. At the end of the treatment, the 
rats were housed individually in metabolic cages without providing food for a day. Urine samples were 
collected from 20:00 p.m. to 8:00 a.m. on the following day. The blood sample was collected via 
abdominal aorta puncture, stabilized with sodium heparin, and then centrifuged at 5000 rpm for 10 min. 
All samples were then stored at  −80 °C for use.  The uterus was removed and weighed immediately. ALP, 
TRAP,  SOD  and  GSH activities  and MDA content  were measured on an automatic analyzer 
(Ciba-Corning 550, USA) using diagnostic reagent kit in vitro determination. The level of estradiol (E2) 
was determined using a specific and sensitive double-antibody RIA kit on a gamma-ray counter. This 
experiment was approved by the Bioethic Committee of the Second Military Medical University, and the 
procedures of the experiment were performed strictly according to the generally accepted international 
rules and regulations. 
2.5. 
1HNMR Spectroscopy 
Urine or plasma samples were defrosted and centrifuged at 10,000 rpm for 10 min before 
1HNMR 
detection. 400 μL supernatant was transferred into NMR tubes (diameter, 5 mm), with addition of  
200 μL PBS buffer solution, 100 μL D2O and 50 μL DSS (2, 2-dimethylsilapentane-4-sulfonic acid,  
1 mM final concentration, internal standard). 
1HNMR measurement was made on a Bruker AVANCE II 
600 spectrometer at 600. 13 MHz 
1H frequency (Bruker Spectrospin AG, SWISS). 
1HNMR spectra of 
the urine and plasma samples were acquired using a solvent pre-saturation pulse sequence to suppress 
the residual water resonance. Free induction decays (FIDs) were collected at 64 K data points, at 300 K, 
with a spectral width of 7200 Hz and an acquisition time of 2.04 s, giving a total pulse recycle delay of 
3.04 s. The data were zerofilled by a factor of 2, and FIDs were multiplied by an exponential weighting 
function equivalent to a line broadening of 0.3 Hz prior to Fourier transformation.  
2.6. Multivariate Statistical Analysis 
The phase and baseline of all 
1HNMR spectra were manually corrected using MestReNova software 
(Mestre, Inc.). The range of δ 10–0 ppm in standard 
1HNMR spectra were automatically segmented into 
500 regions at 0.02 ppm intervals with δ 4.5–5.2 ppm (spectral region incorporating water) set to zero Int. J. Mol. Sci. 2011, 12                       
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integrals. The data of each sample were normalized to total area to correct for the NMR response shift. 
The final data were submitted to SIMCA-P (Version 11.0, Umetrics, Umea, Sweden) software package 
for multivariate analysis. The data were mean-centered and pareto-scaled before this analysis. Then 
Partial least square discriminant analysis (PLS-DA), which has been widely used in metabonomic 
studies [15–17], was performed to clarify which chemical shift regions carry the separating information. 
Cross-validation was used to validate the PLS-DA model according to the default settings in the software. 
2.7. Statistics Analysis 
All numerical data are presented as mean ± SD from replicate experiments. Student’s t-test and 
one-way analysis of variance (ANOVA) were used to evaluate differences between groups. The 
significance level was set at P < 0.05 for all tests. Statistical analysis was performed using PASW 
version 18.0 software (SPSS Inc., Chicago, IL, USA). 
3 Results and Discussion 
3.1. Histopathology 
Ovariectomy induces bone loss, body weight gain and uterine weight reduction. As shown in Table 1, 
there was no significant difference in the initial body weight between the three groups at the beginning 
of the study. At the end of the study, there was a significant increase in body weight in OVX and OVX + 
EXD animals. As expected, the mean uterine weight of OVX animals was significantly lower than that 
of sham controls. It is noteworthy that the mean uterine weight of OVX + EXD animals was identical to 
that of OVX animals. In addition, ovariectomy induced a decrease in serum E2, and EXD treatment 
improved E2 level compared with the OVX model group. Serum TRAP is a biochemical marker of bone 
resorption, and ALP is a marker of bone formation. Our results showed that ovariectomy induced high 
bone turnover in rats, the femur BMD significantly decreased after 12 weeks of ovariectomy compared 
with sham rats, while serum ALP and TRAP levels significantly increased. Administration of the EXD 
extract significantly increased BMD of the femur, and decreased serum ALP and TRAP levels. These 
results indicate that ovariectomy induces osteoporosis of rats, and the EXD extract improved BMD of 
the femur and decreased bone loss induced by ovariectomy.  
Table 1. Osteoporosis-related indexes in control, OVX and Er-Xian Decoction (EXD) treatment group. 
Group  Body weight(g)  Uterine index  E2 
(pg/mL) 
BMD 
(g/cm
2) 
TRAP 
(IU/L) 
ALP 
(IU/L)  Intial  Final 
Sham  251 ± 19  287 ± 10  4.0 ± 1.6  35.7 ± 2.6  0.26 ± 0.01  7.2 ± 1.9  80.6 ± 20.1 
OVX  242 ± 6  346 ± 25 
##  1.1 ± 0.7 
##  16.7 ± 1.8 
##  0.25 ± 0.01 
#  15.0 ± 2.6 
##  109 ± 20.2 
# 
EXD  253 ± 10  339 ± 32  1.8 ± 1.1  28.4 ± 2.2 **  0.26 ± 0.01 *  3.3 ± 1.4 **  86.8 ± 18.2 * 
The uterine index is uterine weight /body weight × 1000; 
# P < 0.05, 
## P < 0.01 compared with sham group;  
* P < 0.05, ** P < 0.01 compared with OVX group. 
3.2. Metabonomic Analysis of Osteoporosis Based on 
1HNMR Metabolic Profiles in Rat Urine and Plasma 
Typical 
1HNMR spectra of plasma and urine samples are shown in Figure 1A,B respectively, with 
major metabolites in the integrate regions assigned. The resonance assignments were made according to Int. J. Mol. Sci. 2011, 12                       
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published reports and the Metabonomics Toolbox (http://www.hmdb.ca) [18]. PLS-DA was used to 
analyze all the 
1HNMR metabolite profiles, and the separation was readily detected. The reliability of the 
established PLS-DA models was evaluated by the explained variation R
2 and the predicted total variation 
Q
2  which is calculated by cross-validation. The expected R
2  and  Q
2,  highly dependent on their 
application fields, should respectively be more than 0.5 and 0.4 for significant biological model[19]. In 
our established model for postmenopausal osteoporosis of rats, the value of R
2 and Q
2 were above 0.6, 
indicating that the PLS-DA model was established successfully (Table 2). The scores plots of urine 
samples (Figure 2A) and plasma samples (Figure 2C) showed well separation between sham and OVX 
groups, indicating that the metabolic characteristics of the two groups were markedly different. The 
corresponding loading plot of urine (Figure 2B) and plasma (Figure 2D) shows the contribution of 
variables to the differences between the OVX and sham groups. The farther the variable deviates from 
the origin, the higher value of variable importance projection (VIP) will be obtained. When VIP value is 
≥1.0, the variable can be considered as a contributor for the classification of OVX and sham groups. 
Twenty six characteristic resonances in urine and 34 in plasma were found in the ovariectomized rats 
(VIP value ≥1), and 10 significant altered metabolites in plasma and 9 in urine were identified as  
listed in Table 3. 
Table 2.  Summary of the parameters for assessing quality of the partial least squares 
discriminant analysis (PLS-DA) model. 
Model  No.
α  R
2X  R
2Y  Q
2 
OVX-Sham         
Plasma  3  0.768  0.78  0.612 
Urine  3  0.756  0.88  0.626 
OVX-Sham-EXD         
Plasma  3  0.792  0.602  0.625 
Urine  3  0.504  0.876  0.685 
No.
α: represent the number of principal component obtained by cross-validation. R
2X: Variation explanation in 
X; R
2Y: the variation explanation in the response to Y; Q
2: Predict variation capability of compound. 
Figure 1. Representative 600 MHz 
1H nuclear magnetic resonance spectroscopy (
1HNMR) 
spectra (δ  10–0.5 ppm) of plasma (A) and urine sample (B) in sham rats.  GPC: 
glycerophosphatide choline; TMAO: Trimethylanine-oxide; OAC: O-acetyl-glucoprotein; 
NAC: N-acetyl-glucoprotein. 
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Figure 1. Cont.  
 
Figure 2. PLS-DA scores plot (A) and corresponding loadings plot (C) are based on the 
1H 
NMR spectra of the plasma samples from Sham (■) and OVX(◆); Scores plot (B) and 
corresponding loadings plot (D) are based on the 
1HNMR spectra of the urine samples from 
Sham(■) and OVX(◆). 
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Table 3. The identified biomarkers in ovariectomized osteoporotic rats and the reverse effects of EXD. 
  Compounds  Group 
δH 
(ppm) 
a OVX 
b EXD  Pathway 
Physiological action in bone 
metabolism 
Plasma  LDL/VLDL  −(CH2)n  1.28–1.32 
↑  ↓  PPAR signaling pathway 
Lipid oxidation products 
(LPO) inhibit osteoblast 
differentiation [20,21]; 
Elevated LDL are associated 
with low BMD [22] 
    −CH3  0.86–0.9 
  Choline  N(CH3)3  3.24  ↑  ↓  Ether lipid metabolism 
Elevated lipid inhibit bone 
remodeling [22,23] 
  Lactate  βCH2  1.34 
↑  ↓  Glycolysis/Gluconeogenesis 
ATP improve osteoclast (OC) 
formation and  
inhibit osteoblast (OB) 
proliferation [24] 
    CH2O  4.14 
  Lipids  CH2CH=  5.3–5.34  ↑  ↓  Peroxisome 
Lipid peroxides altered bone 
oxidative system [21] 
  Lipids  CH2C=CH  2.78–2.82  ↑  ↓  Glycerolipids metabolism 
OVX increase hepatic lipid 
production [19] 
  Alanine  αCH3  1.5  ↓  ↑ 
Alanine, aspartate and glutamate 
metabolism 
 
  Acetoacetate  O=CCH3  2.26  ↑  ↓ 
Valine, leucine and Isoleucine 
biosynthesis 
 Int. J. Mol. Sci. 2011, 12                       
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Table 3. Cont. 
  Compounds  Group 
δH 
(ppm) 
a OVX 
b EXD  Pathway 
Physiological action in bone 
metabolism 
  Glucose  H4  3.44 
↑  ↓ 
Carbohydrate metabolism 
Glucose level related with OB 
proliferation [25], Ca uptake 
[26], bone formation [25,26] 
and lipid metabolism [23,27] 
    H2  3.5 
    H6  3.86, 3.92 
  α-glucose  αCH  5.26    ↑ 
  Isoleucine  γ CH3  0.92  ↓  ↑ 
Valine, leucine and Isoleucine 
biosynthesis 
 
 
Acetyl- 
glucoprotein 
=OCNH  2.02–2.06  ↑  ↓ 
Glutamine and D-glutamate 
metabolism 
Glu inhibit OC formation and 
increase BMD [28] 
 
Glycerophosphatide 
choline 
ON(CH3)3  3.28    ↑  Ether lipid metabolism   
  Creatine  NH2C=O  3.94    ↑  Arginine and Purine metabolism   
Urine               
  Glycine  N−CH2  3.48–3.5  ↑  ↓ 
Glycine, serine and threonine 
metabolism 
 
  Glutamate  βCH2  2.24  ↓  ↑  Glutamate metabolism  [28] 
  Glucose  H6’  3.74, 3.86 
↓  ↑  Carbohydrate metabolism   
    H2  3.58–3.66 Int. J. Mol. Sci. 2011, 12                       
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Table 3. Cont. 
  Compounds  Group 
δH 
(ppm) 
a OVX 
b EXD  Pathway 
Physiological action in bone 
metabolism 
  Taurine  βCH2  3.46–3.44  ↓  ↑  Taurine and hypotaurine 
metabolism 
Taurine inhibit the formation of 
OC [29] and 
    αCH2  3.36–3.38      induce OB proliferation [30] 
  Allantoin  CH  5.4  ↑  ↓  Purine metabolism   
  Alanine  αCH3  1.48–1.5  ↓  ↑ 
Alanine, aspartate and glutamate 
metabolism 
 
  β-Hydroxy Butyrate    4.28  ↑  ↓  Butanoate metabolism   
  Hippurate 
C6H ring 
C2H ring 
7.86–7.9 
7.58 
↑  ↓  Phenylalanine metabolism   
  Lactate  CH2O  4.14–4.1 
↑  ↓  Glycolysis/Gluconeogenesis   
    βCH2  1.34 
  Tryptophane  C4H,ring  7.5–7.52    ↑ 
Glycine,serine and threonine 
metabolism 
 
  Citrate  CH2COO  2.72    ↑  Citrate cycle   
  Creatine  NH2C=O  4.0–4.04    ↑  Arginine and Purine metabolism   
  2-oxo-glutamate  OOCCH2  2.98, 2.08    ↑  Citrate cycle   
a  ↑and  ↓  represent up- and down-regulation of the compound in OVX group compared with the sham group. 
b  ↑and  ↓  represent  up- and 
down-regulation of the compound in EXD group compared with the OVX group. 
 Int. J. Mol. Sci. 2011, 12                       
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3.3. Biological Significance of the Potential Biomarkers in the Osteoporotic Rats 
Ten endogenous metabolites in plasma and nine endogenous metabolites in urine were selected as 
potential biomarkers from VIP and loading plots together to get a complete picture. To get more 
information on the reference of these metabolites, we searched the KEGG PATHWAY Database 
(http://www.genome.jp/kegg/) [31], and found that the altered metabolites are mainly involved in lipid, 
energy and amino acid metabolism.  
As shown in Table 3, the increased plasma levels of low density lipoprotein (LDL), choline, lipids 
and glycerophosphatide choline in ovariectomized rats indicated  that the biological mechanism of 
osteoporosis is associated with lipid metabolism. The findings that there is a connection between lipid 
metabolism and bone remodeling proved by other investigations. OVX-induced estrogen withdrawal 
resulted in both bone loss and an increase in fat [32]. Osteoporotic postmenopausal women have a higher 
level of lipids in blood [20], and statin, a lipid-lowering drug, increased BMD in clinical studies [21,33]. 
Excess fat induces bone loss, and free fatty acid is a strong candidate for the cause of bone loss by 
increasing osteoclast formation  [23].  Therefore, the changes of lipids in blood may predict the 
abnormality of bone metabolism. 
We can see from Table 3 that the levels of lactate and glucose, which are associated with energy 
metabolism, were significantly increased in plasma and urine of the ovariectomized rats, indicating that 
ovariectomy affects the energy metabolism and utilization. It has been reported that ovariectomy and 
etrogen deficiency led to decreased energy expenditure[27], increased glucose level and increased 
visceral adipose tissue [34,35]. Long-term estrogen deficiency may lead to reduction of insulin secretion, 
thus weakening the ability of controlling glucose level in ovariectomized rats [26]. The elevated glucose 
concentration stimulated cellular proliferation during the development of murine osteoblasts [25], while 
inhibiting calcium uptake. Extracellular ATP and other nucleotides can exert impressive stimulatory 
effects on the formation and activity of osteoclasts (bone-resorbing cells), in addition to inhibiting bone 
formation by osteoblasts [24].
 It may be speculated that ovariectomy and estrogen deficiency led to 
disturbance of energy metabolism, and further the imbalance of bone remodeling. 
In the formation of postmenopausal osteoporosis, the amino acid metabolism is also definitely 
disturbed. This can be seen from the urine metabolite profile of OVX rats. As shown in Table 3, the 
levels of glycine, allantoin and hippurate were upregulated, and taurine, glutamate and alanine were 
down-regulated in the urine of OVX rats, some of which were involved in the bone remodeling. Taurine, 
which is found in a high concentration in bone cells, is thought to inhibit the formation and survival of 
osteoclasts [29,36], induce cell proliferation and differentiation in human osteoblast (HOB) cells [30].  
In the present study, urine taurine level in the OVX rats decreased dramatically. This might indicate the 
increased utilization or decreased excretion of taurine because of the stress reaction of ovariectomy. 
L-glutamate (Glu), which is an excitatory amino acid neurotransmitter in the mammalian central nervous 
system, could markedly inhibit osteoclastogensis, prevented BMD from decreasing in ovariectomized 
mice  [28]. In our study,  urine  glutamate  was  reduced in the ovariectomized rats, indicating  that 
ovariectomy resulted in decreased glutamate production, which further affected the bone remodeling. 
Urine taurine and glutamate may prove to be useful biomarkers for evaluating the risk of osteoporosis 
and fracture. Int. J. Mol. Sci. 2011, 12                       
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3.4. Metabonomic Analysis of EXD Treatment 
According to the histopathology results (Table 1), EXD treatment had a positive effect on the OVX 
model in characteristic osteoporosis-related indexes, including BMD, ALP and TRAP activity. All of 
the values of R
2 and Q
2 in our established PLS-DA models are more than 0.5, so this model can be used 
to differentiate the OVX rats from the sham and the EXD-administrated rats by analyzing the 
1HNMR 
data. As shown in Figure 3A,B, the dots of EXD treatment group were closer to sham group and far 
away from OVX group, which might suggest that  EXD reversed  the pathological process of 
OVX-induced osteoporosis. Most of the biomarkers in Table 3 could be reversed to normal levels or 
close to normal levels by EXD intervention. Nine metabolites, including lipids, choline, LDL, lactate, 
glucose, glutamate, glycine and taurine, which are all related to the lipid or amino acid metabolism as 
mentioned above, were completely  reversed to normal levels  by  EXD  (Figure  4).  In addition,   
EXD significantly up-regulated  the metabolite levels related to energy metabolism, including 
glycerophosphatide choline, citrates, creatine and 2-oxo-glutamate, and also increased the urine level of 
tryptophane, which is a precursor for serotonin. Serotonin has been shown to increase bone mass by 
increasing the recruitment and proliferation of osteoblasts. The results of histopathology and 
metabonomics demonstrated  that  EXD  had extensive effects in the treatment of postmenopausal 
osteoporosis through regulating the disturbed pathways of lipid, energy and amino acid metabolisms. 
Figure 3. Scores plot from PLS-DA of 
1HNMR data of urine (A) and plasma (B) samples 
obtained from control rats, OVX rats and EXD treatment rats. 
 Int. J. Mol. Sci. 2011, 12                       
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Figure 4. The relative levels of nine significantly altered metabolites in the rats of sham, 
OVX and EXD treatment groups. The percentage has been calculated with the formula: 
Contents in groups /content in control group × 100%. P—plasma, U—urine. 
## P < 0.01,  
# P < 0.05 compared with sham group; ** P < 0.01, * P < 0.05 compared with OVX group. 
 
3.5. Determination of Superoxide Dismutase Activity, Glutathione Peroxidase Activity and 
Malondialdehyde Content 
The altered metabolites in plasma and urine of ovariectomized rats such as lipids, LDL, taurine and 
glutamate are involved in the oxidative defense system. Some studies [37,38] showed that ovariectomy 
induced oxidative stress, impaired the bone antioxidant system in adult rats, increased the production of 
lipid peroxidation and H2O2, and reduced the enzymatic antioxidants like SOD and GSH-Px in rats. This 
correlation of oxidative stress and bone metabolism can also be further illustrated by the correlation 
between plasma oxidative state and BMD. Plasma total oxidative status value is significantly higher, and 
plasma total antioxidant level was lower in osteoporotic patients than that in healthy controls, and there 
is a significant negative correlation between total oxidative value and BMD in lumbar and femoral neck 
region [21]. EXD had an anti-aging effect in that it raise the activities of antioxidant enzymes, such as 
SOD, CAT, and reduce the production of free radicals [39]. To confirm this mechanism, we evaluated 
the levels of SOD, GSH activity and MDA content in serum of ovariectomized rats. As shown in Figure 
5A–C, serum levels of SOD and GSH in OVX model rats were significantly decreased, and the content 
of MDA significantly increased compared with the sham rats (P < 0.05), while this alteration could be 
reversed by the intervention of EXD treatment (P < 0.05), indicating that oxidation is involved in the Int. J. Mol. Sci. 2011, 12                       
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pathological process of postmenopausal osteoporosis, and EXD prevents osteoporosis by involving the 
oxidative system. 
Figure 5. The activity of SOD (A), GSH (B) and the content of MDA (C) in serum of rats of 
sham, OVX and EXD treatment groups. 
## P <0.01, 
# P < 0.05 compared with sham group; 
** P < 0.01, * P < 0.05 compared with OVX group. 
 
4. Conclusion 
In this study, an NMR-based metabonomic approach has been successfully established to study 
metabolic changes in osteoporotic ovariectomized rats and action mechanism of EXD. As a result, lipid 
metabolism, energy metabolism, and amino acid metabolism changed in ovariectomized rats. Some 
altered metabolites were involved in the oxidative defense system, and the levels of SOD and GSH were 
significantly reduced, and the content of MDA was  increased in the serum of ovariectomized 
osteoporotic rats. EXD could reverse the pathological process of osteoporosis through regulating the 
disturbed pathway of lipid, energy and amino acid metabolism, improve the activity of SOD and GSP, 
and decrease the content of MAD in the serum of OVX rats. Our findings reveal distinct metabolic 
changes in osteoporosis, and may be helpful for further understanding of this disease. Furthermore, the 
detected pathway alteration may be useful for the development of new drug targets for the treatment  
of osteoporosis. 
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